- Home
- NNE vs AUTL Comparison
NNE vs AUTL Comparison
Compare NNE & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNE
- AUTL
- Stock Information
- Founded
- NNE 2022
- AUTL 2014
- Country
- NNE United States
- AUTL United Kingdom
- Employees
- NNE N/A
- AUTL N/A
- Industry
- NNE
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NNE
- AUTL Health Care
- Exchange
- NNE NYSE
- AUTL Nasdaq
- Market Cap
- NNE 718.5M
- AUTL 590.8M
- IPO Year
- NNE 2024
- AUTL 2018
- Fundamental
- Price
- NNE $44.51
- AUTL $2.37
- Analyst Decision
- NNE Strong Buy
- AUTL Strong Buy
- Analyst Count
- NNE 2
- AUTL 3
- Target Price
- NNE $58.00
- AUTL $10.20
- AVG Volume (30 Days)
- NNE 5.6M
- AUTL 1.2M
- Earning Date
- NNE 02-14-2025
- AUTL 03-13-2025
- Dividend Yield
- NNE N/A
- AUTL N/A
- EPS Growth
- NNE N/A
- AUTL N/A
- EPS
- NNE N/A
- AUTL N/A
- Revenue
- NNE N/A
- AUTL $10,091,000.00
- Revenue This Year
- NNE N/A
- AUTL $851.83
- Revenue Next Year
- NNE $272.38
- AUTL $264.18
- P/E Ratio
- NNE N/A
- AUTL N/A
- Revenue Growth
- NNE N/A
- AUTL 82.71
- 52 Week Low
- NNE $3.25
- AUTL $2.07
- 52 Week High
- NNE $48.05
- AUTL $7.37
- Technical
- Relative Strength Index (RSI)
- NNE N/A
- AUTL 46.88
- Support Level
- NNE N/A
- AUTL $2.12
- Resistance Level
- NNE N/A
- AUTL $2.38
- Average True Range (ATR)
- NNE 0.00
- AUTL 0.13
- MACD
- NNE 0.00
- AUTL 0.02
- Stochastic Oscillator
- NNE 0.00
- AUTL 37.23
About NNE NANO NUCLEAR ENERGY INC
Nano Nuclear Energy Inc is an early-stage nuclear energy company developing smaller, cheaper, and safer advanced portable clean energy solutions. It is focused on four business lines as part of development: Micro Nuclear Reactor Business is developing the next-generation nuclear microreactors, in particular ZEUS, a solid core battery reactor, and ODIN, a low-pressure salt coolant reactor. Fuel Fabrication Business, Fuel Transportation Business and Nuclear Consultation Services.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.